Breast Cancer, Colon Cancer, Rectal Cancer
Conditions
Keywords
DigiMeds, Capecitabine, Standard of Care
Brief summary
DigiMeds™ are medications with FDA-approved ingestible sensors (IS), a wearable sensor patch (patch), and a mobile app, which records time-stamped medication type and dose alongside biometric activity. The aim of this registry is to collect and analyze data on the use of DigiMeds™ and a digital feedback system on medication adherence, patient-provider communication, and data-driven optimization of therapy for cancer patients.
Detailed description
Patients will be prescribed the DMP and DigiMeds™ (capecitabine or supportive medications) by their healthcare provider. The pharmacy will co-encapsulate the prescribed medication with a sensor. The actual doses of DigiMeds™ will be based on standard of care as prescribed by treating physician. Patients will be instructed in the use of the DigiMeds™ and the DMP based on standard of care plus use of the DMP system. Every effort should be made to take the DigiMeds™ as prescribed. Patients in this study will be given the option to use their personal smartphone or will be provided a provisioned iPad to use for the duration of the study. Each patient will receive a Starter Kit comprised of two wearable sensor pods, adhesive strips, and instructions. Additionally, some kits may contain the provisional iPad Mini and charger for those without an approved smart device. Should a device malfunction occur, such as a broken pod, the patient can replace it with their spare pod. Broken pods should be returned to Proteus as soon as possible and all pods must be returned to the clinic upon completion of the study.
Interventions
OTHERDigiMeds
Digitized Capecitabine
Sponsors
Proteus Digital Health, Inc.
Study design
Observational model
OTHER
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
* Age ≥ 18 * Prescribed treatment with DigiMeds™ * Have an Android or iOS-enabled device (e.g., iPhone, iPad, Samsung) or be willing to use a Proteus issued iOS device * Signed consent form
Exclusion criteria
* Receiving palliative or hospice care services (i.e., proxy for \<12 months life expectancy) * Not proficient in the English language * Have impaired cognitive ability * For women: current pregnancy * Have skin sensitivity to adhesives or active/chronic dermatitis
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Compare the duration of actual vs. intended treatment for cancer patients on capecitabine who are prescribed capecitabine with sensor. | Up to 6 months from the date of inclusion into study | Determine how long patients can stay on treatment when using DigiMeds |
Countries
United States
Outcome results
None listed